Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Proliferative Vitreoretinopathy: early-phase trial registry
2 of 3 indexed Proliferative Vitreoretinopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Proliferative Vitreoretinopathy: 3 US clinical trials tracked, 2 recruiting.
Proliferative Vitreoretinopathy is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Wills Eye, running 1 of these trials.
Enrollment posture brief
Registry condition proliferative-vitreoretinopathy
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Proliferative Vitreoretinopathy lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Proliferative Vitreoretinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Proliferative Vitreoretinopathy is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Cincinnati Eye Institute, Southwest Ohio
NCT06541574
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Massachusetts Eye and Ear Infirmary
NCT06033703
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
Wills Eye
NCT05660447
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Proliferative Vitreoretinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Proliferative Vitreoretinopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Proliferative Vitreoretinopathy page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Proliferative Vitreoretinopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Wills Eye sponsors the most Proliferative Vitreoretinopathy trials on record, review their full trial history before evaluating a specific study. See Wills Eye's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Proliferative Vitreoretinopathy condition card totals 3 registered trials; most-linked intervention Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.